Importance of thiopurine S-methyltransferase gene polymorphisms for prediction of azathioprine toxicity

Neuroendocrinology Letters

Volumn 30, Issue SUPPL.1, 2009, Pages 137-142

  Kolorz, Michal ^a   Bartosova, Ladislava ^a   Hosek, Jan ^a   Dvorackova, Dana ^a   Chylkova, Alicja ^a   Zboril, Vladimir ^b   Batovsky, Marian ^c   Bartos, Milan ^a  

^a UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c SLOVAK MEDICAL UNIVERSITY   (Slovakia)

Author keywords

Azathioprine; Inflammatory bowel disease (IBD); Leucopenia; Pharmacogenetics; Thiopurine S methyltransferase (TPMT)

Indexed keywords

AZATHIOPRINE; DRUG METABOLITE; THIOPURINE METHYLTRANSFERASE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PREDICTION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 77349123020     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Braat H, Stokkers P, Hommes T, Cohl D, Vogels E, Pronk I, et al (2005). Consequence of functional Nod2 and Tlr4 mutations on gene transcription in Crohn's disease patients. J Mol Med. 83: 601-609.
2. Coulthard SA, Rabello C, Robson J, Howell C, Minto L, Middleton PG, et al (2000). A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. Br J Haematol. 110: 599-604.
3. Krynetski EY, Tai H-L, Yates CR, Fessing MY, Loennechen T, Schuetz JD, et al (1996). Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics. 6: 279-290.
4. Krynetskaia NF, Cai X, Nitiss JL, Krynetski YE, Relling MV (2000). Thioguanine substitution alters DNA cleavage mediated by topoisomerase II. FASEB J. 14: 2339-2344.
5. Krynetski EY, Schuetz J, Galpin A, Pui C, Relling M, Evans W (1995). A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA. 92: 949-953.
6. Lavy A, Chowers Y, Odes H S, Eliakim R (2003). Position statement: Immunomodulator therapy for inflammatory bowel disease. IMAJ. 5: 164-169.
7. Lennard L, Gibson BE, Nicole T, Lilleyman JS (1993). Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukemia. Arch Dis Child. 66: 577-579.
8. Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV et al (2001). Leucopenia resulting from a frug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 49: 656-664.
9. Maes M (2008). The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as a new targets for adjunctive treatments in depression. Neuroendocrinol Lett. 29: 287-291.
10. Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM, et al (2004). Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics. 14: 181-187.
11. McLeod HL, Pritchard SC, Githang'a J, Indalo A, Ameyaw MM, Powrie RH et al (1999). Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 9: 773-776.
12. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah Joet al (1997). Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther. 62: 60-73.
13. Ponticelli C, Tarantino A, Vegeto A (1999). Renal transplantation, past, present and future. J Nephrol. 12: S105-110.
14. Sahasranaman S, Howard D, Roy S (2008). Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 64: 753-767.
15. Seki T, Tanaka T, Nakamura Y (2000). Genomic structure and multiple single-nucleotide polymorphisms (SNPs) of the thiopurine S-methyltransferase (TPMT) gene. J Hum Genet. 45: 299-302.
16. Schaeffeler E, Fisher C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M et al (2004). Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variant. Pharmacogenetics.14: 407-417.
17. Stanulla M, Schaefeller E, Flohr T, Cario G, Schrauder A, Zimmermann M et al (2006). Thiopurine Methyltransferase (TPMT) Genotype and Early Treatment Response to Mercaptopurine in Childhood Acute Lymphoblastic Leukemia. JAMA. 293: 1485-1489.
18. Tai HL, Krynetski EY, Schuetz EG, et al (1997). Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): Mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl. Acad. Sci. USA. 94: 6444-6449.
19. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M (2007). Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 46: 187-208.
20. Tracey D, Klareskog L, Sasso E H, et al (2008). Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacology& Therapeutics. 117: 244-279.
21. Wang XL, Lu JM, Yang LJ, Lu ZH, Dou JT, Mu YM et al (2008). A case of relapsed autoimmune hypothalamitis successfully treated with methylprednisolone and azathioprine. Neuro Endocrinol Lett. 29: 874-876.
22. Weber WW (2001). The legacy of pharmacogenetics and potencial applications. Mutation Research. 479: 1-18.
23. Wei H, Zhou S, Li Ch, Zhang J, Wu J, Huang M (2005). Phenotyping and genotyping studies of thiopurine S-methyltransferase in Kazaks. Pharmaceutical Research. 22: 1762-1766.
24. Weinshilboum R (2003). Inheritance and drug responce. N Engl J Med. 6: 529-537.
25. Yammoto-Furusho JK, Podolsky DK (2007). Innate immunity in inflammatory bowel disease. World J Gastroenterol. 14: 5577-5580.
26. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH et al (1997). Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathiopurine and mercaptopurine intolerance. Ann Intern Med. 126: 608-614.
27. Zhang JP, Guan YY, Xu AL, Zhou SF, Wu JH, Wei H, et al (2004). Gene mutation of thiopurine S-methyltransferase in Uygur Chinese. Eur J Pharmacol. 60: 1-3.